Research Reports

Key takeaways

Stockholders approved a proposal authorizing the Board to effect a reverse stock split at a ratio between 1-for-10 and 1-for-30.

The Board approved a specific reverse stock split ratio of 1-for-10, set to be effective at 12:01 a.m. Eastern Time on April 27, 2026.

The post-split common stock will begin trading on the Nasdaq Capital Market under the existing symbol 'IMUX' on April 27, 2026.

Approximately 54.1% of outstanding shares were represented at the Special Meeting, with 57.4 million votes cast in favor of the split proposal.

Full analysis

Immunic, Inc. secured stockholder approval for a reverse stock split during a Special Meeting held on April 14, 2026. The proposal, which passed with 57.4 million votes in favor versus 12.6 million against, granted the Board discretion to implement a split within a 1-for-10 to 1-for-30 range. Following this authorization, the Board exercised its discretion to fix the ratio at 1-for-10. The split is scheduled to become effective at 12:01 a.m. Eastern Time on April 27, 2026. Management stated that the post-split shares will continue to trade on the Nasdaq Capital Market under the ticker symbol 'IMUX' with a new CUSIP identifier. This corporate action significantly alters the share structure, reducing the number of outstanding shares, and is typically undertaken to meet exchange listing requirements or broaden the stock's appeal.

IMUX · Immunic, Inc.

Summary

Key takeaways

Full analysis